A troubling revelation has emerged regarding a widely used daily supplement favored by millions of Americans.
Across the nation, many older adults have turned to a popular supplement often claimed to enhance brain health and potentially help in preventing dementia.
However, recent research challenges this belief, indicating that those who regularly consume these capsules may actually experience a faster cognitive decline.
The supplements in question are omega-3 fatty acids, commonly referred to as omega-3s.
These capsules deliver concentrated amounts of essential fats that the body cannot produce independently. As a result, individuals obtain them through dietary sources or supplements, which are frequently marketed as beneficial for brain, heart, and joint health.
Notably, one of the most prevalent forms—fish oil—is consumed daily by nearly 1 in 5 Americans over 60, according to a 2023 report.
In this ground-breaking study, researchers in China monitored over 800 older adults across five years, utilizing repeated cognitive assessments and brain imaging techniques.
The participants were divided into two groups: 273 individuals who took omega-3 supplements and 546 who did not.
Approximately half of the participants in both cohorts were carriers of the APOE ε4 gene, which is associated with a heightened risk of Alzheimer’s disease, the most prevalent form of dementia.
After adjusting for variables such as age, gender, genetics, and diagnosis, the researchers found that those using omega-3 supplements experienced a more significant decline in cognitive function across three assessments throughout the study.
This trend persisted regardless of genetic factors, indicating that the presence of the APOE ε4 gene alone could not account for the observed differences.
This is particularly noteworthy because previous research has suggested that carriers of this gene may react differently to omega-3 intake compared to non-carriers.
To explore the underlying causes of this accelerated decline, researchers examined the participants’ brain scans.
Surprisingly, the deterioration among supplement users did not correlate with an accumulation of amyloid plaques or tangled tau proteins—standard indicators of Alzheimer’s disease.
Instead, the scans indicated a marked reduction in brain glucose metabolism among the omega-3 group, implying that their brain cells were less adept at utilizing sugar for energy.
Researchers hypothesize that the supplements may disrupt this metabolic process, impairing the communication between synapses—the minute gaps that facilitate signal transmission between cells.
If brain cells struggle to efficiently use energy, this communication network might begin to falter, potentially accelerating cognitive decline before any physical damage becomes apparent on imaging studies.
“These findings challenge the prevailing belief that omega-3 is always beneficial and underscore the need for a careful reevaluation of its widespread usage for cognitive enhancement,” the study’s authors stated.
The researchers emphasized that the observational nature of the study does not establish a direct causative link between omega-3 supplements and accelerated cognitive decline. Nevertheless, the insights provide a new avenue for scientific exploration.
The body of research surrounding omega-3s and cognitive health has been inconsistent over the years. Some studies have linked the supplements to improved cognitive outcomes, while others have indicated little to no effect.
Experts suggest that whole-food sources of omega-3s—like salmon and other fatty fish—may yield different results due to their comprehensive mix of nutrients, which act in synergy in ways that isolated supplements may not.
These findings come amid increasing concerns about cognitive decline as a health crisis in the United States.
Nearly one-third of individuals aged 65 and older currently experience some form of cognitive impairment affecting memory, thought processes, and daily decision-making. Approximately 10% are diagnosed with dementia.
Experts caution that this trend is likely to intensify as the population ages and people live longer.
A 2025 study predicts that the United States may see 1 million new dementia cases annually by 2060—approximately double the current rate.
